oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Lipidomics-based safety biomarkers for lipid-lowering treatments
Science Center, Tampere University Hospital, Tampere, Finland; Zora Biosciences Oy, Espoo, Finland.
Zora Biosciences Oy, Espoo, Finland.
Zora Biosciences Oy, Espoo, Finland; VTT Technical Research Centre of Finland, Espoo, Finland.ORCID iD: 0000-0002-2856-9165
2008 (English)In: Angiology, ISSN 0003-3197, E-ISSN 1940-1574, Vol. 59, no 2 Suppl, p. 65S-68SArticle in journal (Refereed) Published
Abstract [en]

Recent data suggest that aggressive lipid-lowering treatment results in significant reductions of atherosclerotic complications, ie, strokes, heart attacks, or peripheral vascular diseases. Thus, more patients will be titrated to higher doses of statins in order to reach the aggressive targets of low-density lipoprotein- cholesterol reduction. However, aggressive treatment with high statin doses has increased the risk of statin-induced myopathy. The incidence of myopathy in cohort studies and in randomized trials has been low, supporting the good safety profile of statin drugs. However, muscle effects seem to be more frequent in clinical practice. Of all statin users, approximately 1% to 5% suffers from muscular symptoms caused by medication. This potentially reduces the compliance toward treatment and number of patients reaching their treatment targets due to withdrawal of therapy. Thus, novel biomarkers are needed for prediction or improved diagnoses of statin-induced side effects. This would potentially increase the quality of life of patients and improve treatment results. Using lipidomic analysis, we found that the plasma lipidomic changes following simvastatin treatment correlate with the muscle expression of the arachidonate 5-lipoxygenase-activating protein. Intriguingly, these results suggest that the plasma lipidomic profile may serve as a highly sensitive biomarker of statin-induced metabolic alterations in muscle and may thus allow us to identify patients who should be treated with a lower dose to prevent a possible toxicity.

Place, publisher, year, edition, pages
Westminster Publications , 2008. Vol. 59, no 2 Suppl, p. 65S-68S
Keywords [en]
Statins, myopathy, lipidomics, biomarkers
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:oru:diva-70916DOI: 10.1177/0003319708321106ISI: 000259361800011PubMedID: 18632766Scopus ID: 2-s2.0-53049091782OAI: oai:DiVA.org:oru-70916DiVA, id: diva2:1345903
Available from: 2019-08-26 Created: 2019-08-26 Last updated: 2019-08-30Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Oresic, Matej

Search in DiVA

By author/editor
Oresic, Matej
In the same journal
Angiology
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 6 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf